Why 'normal' vitamin B12 may miss brain aging risk

A new Annals of Neurology paper from UCSF points to an awkward possibility for older adults: a vitamin B12 result can sit well inside the standard laboratory range and still miss a brain under strain. In a cohort of 231 healthy adults with a median age of 71.2 years, the clearest signals did not come from outright deficiency. They came from subtler differences in the biologically active form of B12.

What gives the study its bite is where the signal showed up. The authors found that lower holotranscobalamin, the fraction of B12 that is actually available for cells to use, tracked with slower processing speed in older participants, delayed visual evoked potentials, and more white-matter hyperintensities on brain imaging. Median total B12 in the cohort was 414.8 pmol/L, well above the familiar U.S. deficiency cutoff of 148 pmol/L. The paper reads less like a case for panic than a case against false reassurance.

Skeptics should object early. This was an association study, not a trial that proved raising B12 reverses brain aging or prevents cognitive decline in people who are merely low-normal. Vitalspell readers should treat it as a biomarker paper first. Its force lies in showing that the phrase normal B12 may hide too much biology, not in blessing a new round of memory-supplement marketing.

Why total B12 can miss the neurologic signal

Serum total B12 is a blunt measure. It counts what is circulating, but not necessarily what is reaching tissue in a form the nervous system can use. The more revealing marker in this paper was holo-transcobalamin, often shortened to holoTC, which the authors treated as active B12. That distinction matters because two people can post similar total B12 values while carrying very different amounts of usable vitamin.

On a routine lab report, total B12 tells you how much vitamin is present somewhere in the bloodstream. HoloTC gets closer to how much is attached to the transport protein that can deliver it to cells. Those are related questions, not identical ones. In an older population that can still look broadly healthy on routine screening, that gap may be where a neurologic signal first appears.

At the study’s geometric mean total B12 level of 408 pmol/L, the split looked numeric. The more important divide was functional. Lower holoTC was associated with slower visual processing and delayed signals on electrophysiology testing, both clues that the nervous system may be paying attention to B12 status before a standard deficiency flag appears. The paper also found that higher holo-haptocorrin, an inactive transport fraction, tracked with higher tau. That is a useful corrective to the folk idea that more B12 in a blood tube automatically means more protection for the brain.

Ari J. Green, the senior author, put the problem plainly in a UCSF summary of the study:

“Previous studies that defined healthy amounts of B12 may have missed subtle functional manifestations of high or low levels that can affect people without causing overt symptoms.”

— Ari J. Green, UC San Francisco

Older literature fits that reading better than the one-number lab story does. In a 2007 cohort study in the American Journal of Clinical Nutrition, Clarke and colleagues reported that low holoTC and high methylmalonic acid predicted faster cognitive decline in older adults, while total serum B12 was less informative on its own. A 2016 longitudinal MRI study of older adults reached a similar place from a different angle: higher baseline B12 and holotranscobalamin were linked with slower total brain-volume loss over time. Taken together, those studies partially answer the analyst’s central question. Active B12 seems to describe neurologic risk more cleanly than total B12 alone.

What the paper can and cannot tell you

The more uncomfortable question is what anyone should do with a low-normal result. This study cannot answer that on its own. The participants were healthy older adults, not patients randomized to treatment versus placebo, and the outcomes were biomarker and performance associations rather than a clinical demonstration that supplements stopped decline. There is a long distance between identifying a better warning light and proving that intervening at that point changes the road ahead.

Put another way, this is a paper about earlier classification, not ready-made clinical instructions. It suggests that subtle functional insufficiency may sit upstream of overt deficiency. It does not yet show that treating every person in that gray zone will change cognition, MRI findings, or long-term diagnosis.

Alexandra Beaudry-Richard, the co-first author, made the population-level implication explicit in the same UCSF statement:

“These lower levels could impact cognition to a greater extent than what we previously thought, and may affect a much larger proportion of the population than we realize.”

— Alexandra Beaudry-Richard, UC San Francisco

Even here, more is not automatically better. One of the more intriguing findings in the paper was that holo-haptocorrin, the inactive B12 transport fraction, tracked with tau. That does not mean high B12 causes neurodegeneration. It does mean a high total B12 value should not be romanticized as a synonym for optimal brain nutrition. Blood chemistry can reflect transport, storage, and tissue use imperfectly. That is precisely why the paper is unsettling. It turns a supposedly simple vitamin story back into a biomarker-interpretation story.

Skeptics earn their place here because they keep the claim proportionate. The paper suggests that some older adults could be neurologically under-served before they meet a traditional deficiency definition. It does not show that everyone in that middle zone needs a supplement, let alone a high-dose one. It argues for better classification first.

What this could mean for screening older adults

Should the paper hold up, the most plausible change is not a universal instruction to take more B12. It is a change in how clinicians interpret borderline results in older adults, especially when cognitive symptoms or unexplained slowing are part of the picture. The regulator-policy view is less dramatic but probably more consequential: a single cutoff may be too crude, and staged testing that includes functional markers could make more sense than relying on total B12 alone.

Earlier work points in the same direction. A 2015 Swiss cohort study of healthy seniors found that reference limits for B12-related markers varied by age and sex and that holoTC performed well as a marker of deficient status. That is not enough to rewrite practice guidelines by itself. It does, however, strengthen the case for age-aware or biomarker-aware decision limits, which is exactly the policy question this new paper pushes back onto the table.

Real-world care is messier than a biomarker argument on paper. Total B12 testing is cheap, familiar, and easy to scale. Functional markers such as holoTC or methylmalonic acid add complexity, and guideline changes usually demand evidence that better testing improves outcomes, not just correlations. Green hinted at that future in a second university statement, arguing that revisiting B12 deficiency to include functional biomarkers could allow earlier intervention. The operative word is could. That is where the science stands.

Seen that way, clinicians could treat this paper as a prompt, not a prescription. For an older adult with cognitive complaints or an unexpectedly borderline lab picture, a normal total B12 value may be the beginning of the workup rather than the end of it. For everyone else, the study mainly offers a warning against overconfidence in one reassuring number.

For now, the least marketable reading is still the cleanest one. Normal vitamin B12 is not necessarily the same thing as neurologically sufficient vitamin B12 in an aging brain. That should make clinicians and healthy older adults more cautious about over-trusting a single lab number. It should also make readers wary of the opposite overreaction. This paper is a prompt to refine screening and run better trials, not a license for blanket self-supplementation.

References

1. Beaudry-Richard A, Abdelhak A, Saloner R, et al. Vitamin B12 levels association with functional and structural biomarkers of central nervous system injury in older adults. Annals of Neurology. 2025. https://onlinelibrary.wiley.com/doi/10.1002/ana.27200
2. Clarke R, Birks J, Nexo E, et al. Low vitamin B-12 status and risk of cognitive decline in older adults. American Journal of Clinical Nutrition. 2007. https://www.sciencedirect.com/science/article/pii/S0002916523276595
3. Vogiatzoglou A, Refsum H, Johnston C, et al. Association of vitamin B12, folate, and sulfur amino acids with brain magnetic resonance imaging measures in older adults: a longitudinal population-based study. PubMed. 2016. https://pubmed.ncbi.nlm.nih.gov/27120188/
4. Vitamin B12 and folate levels in healthy Swiss senior citizens: a prospective study evaluating reference intervals and decision limits. PMC. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4499201/